Organisation paid for research Program year 2025 Source: CMS Open Payments

Sun Research Institute

Neither a doctor nor a teaching hospital

Research payments

$4,393,608

1,875 payments

Through program year 2025, Sun Research Institute is reported as receiving $4,393,608 in research payments, across 1,875 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$291,341	15
2024	Research	$304,315	45
2023	Research	$382,699	110
2022	Research	$835,989	336
2021	Research	$1,197,118	798
2020	Research	$881,013	262
2019	Research	$501,133	309

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $968,763 17 payments
Novo Nordisk AS $741,657 1,402 payments
Regeneron Pharmaceuticals, Inc. $711,974 63 payments
Moderna TX, Inc. $471,424 52 payments
Allergan Inc. $353,109 80 payments
AstraZeneca UK Limited $332,322 3 payments
AbbVie, Inc. $210,665 106 payments
Novartis Pharmaceuticals Corporation $163,142 1 payment
Celgene Corporation $126,561 20 payments
E.R. Squibb & Sons, L.L.C. $47,557 7 payments

Studies the money was for Research payments · program years 2019–2025

A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $1,117,970 4 payments
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $704,974 62 payments
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $337,049 16 payments
Nn1250-4419 $241,695 53 payments
Ex9536-4388 $192,356 346 payments
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $163,142 1 payment
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $142,733 14 payments
Nn9535-4321 $135,570 195 payments
Nn1436-4478 $99,668 425 payments
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $98,445 25 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.